期刊文献+

利拉鲁肽对2型糖尿病患者心血管的保护作用分析 被引量:2

Analysis of protective effect of liraglutide on cardiovascular in patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的:探讨利拉鲁肽对2型糖尿病患者心血管的保护效果。方法:收治2型糖尿病患者60例,接受二甲双胍+利拉鲁肽治疗,测定患者服药前、服药24周后的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、收缩压(SBP)、舒张压、颈动脉内膜中层厚度(IMT)。结果:相比于治疗前,治疗24周后患者的FPG、2 h PG、Hb A1c、SBP、IMT中层厚度均显著降低(P<0.05)。结论:利拉鲁肽可以平稳地降低血糖,还能通过降压、抗炎等机制保护患者的心脏安全。 Objective:To explore the protective effect of liraglutide on cardiovascular in patients with type 2 diabetes mellitus.Methods:60 patients with type 2 diabetes mellitus were selected.They were treated by metformin plus liraglutide.Before treatment and 24 weeks after medication,fasting blood glucose,postprandial 2 hours blood glucose,glycated hemoglobin,systolic blood pressure,diastolic blood pressure,carotid artery intima-media thickness were measured.Results:Compared with before treatment,at 24 weeks after treatment,fasting blood glucose,postprandial 2 hours blood glucose,glycated hemoglobin,systolic blood pressure,carotid artery intima-media thickness were significantly reduced(P<0.05).Conclusion:Liraglutide can steadily reduce blood sugar.It can protect the cardiac safety through the anti-hypertension,anti-inflammatory mechanism.
作者 曲洪芬
出处 《中国社区医师》 2015年第16期19-19,共1页 Chinese Community Doctors
关键词 2型糖尿病 利拉鲁肽 心血管疾病 Type 2 diabetes mellitus Liraglutide Cardiovascular disease
  • 相关文献

二级参考文献43

  • 1李顺君,黄文芳,饶绍琴,董魏.糖化血红蛋白测定方法学评价[J].检验医学与临床,2007,4(5):381-381. 被引量:52
  • 2Kela R,Davies MJ. Treatment evaluation of liraglutide in type 2 diabetes[J]. Expert Opin Biol Ther, 2012,12(11) ; 1551.
  • 3Varanasi A, Patel P, Makdissi A, et al. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors [J]. Endocr Pract, 2012,18(2): 140.
  • 4Buse JB,Ginsberg HN,Bakris GL,et al.Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific statement from the American Heart Association and the American Diabetes Association.Circulation,2007,115:114-126.
  • 5Eeg-Olofsson K,Cederholm J,Nilsson PM,et al.Risk of cardi ovascular disease and mortality in overweight and obese patients with type 2 diabetes:an observational study in 13,087 patients.Diabetologia,2009,52:5265-52-73.
  • 6Juutilainen A,Lehto S,Ronnemaa T,et al.Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects.Diabetes Care,2008,31:714-719.
  • 7Stratton IM,Adler AI,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study.BMJ,2000,321:405-412.
  • 8Adler AI,Stratton IM,Neil HA,et al.Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):prospective observational study.BMJ,2000,321:412-419.
  • 9Rodbard HW,Jellinger PS,Davidson JA,et al.Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:an algorithm for glycemic control.Endocr Pract,2009,15:540-559.
  • 10Nystrom T,Gutniak MK,Zhang Q,et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patientswith stable coronary artery disease.Am J Physiol EndocrinolMetab,2004,287:E1209-E1215.

共引文献19

同被引文献21

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部